New Abu Dhabi clinical trials using AI to have ‘massive’ impact on health care | The National
Oracle expects its new artificial intelligence partnership with AstraZeneca and Abu Dhabi’s M42 to have a “massive impact” on the region’s healthcare systems by cutting the time and cost of running clinical trials, according to a senior executive at the tech. “It’s going to have a massive impact,” Seema Verma, executive vice president and general manager of Oracle Health and Life Sciences, told The National in an interview on the.
Under the collaboration announced last week, AstraZeneca will pair its scientific development with Oracle’s cloud infrastructure and AI tools to speed up clinical research globally.
It will help clinical teams identify patients with uncontrolled hypertension (high blood pressure), implement care and improve recruitment for trials, the companies said.
- 01Look for the first named pilot, project, customer deployment or delivery milestone under AI access to data.